Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:38:22 EDT Wed 01 May 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:AMRN from 2023-05-02 to 2024-05-01 - 35 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-05-01 07:00
U
U:AMRN
News Release
200
Amarin Reports First Quarter 2024 Business Update and Financial Results
2024-04-24 14:00
U
U:AMRN
News Release
200
Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
2024-04-22 08:00
U
U:AMRN
News Release
200
Amarin Announces Results of Annual General Meeting of Shareholders
2024-04-15 08:00
U
U:AMRN
News Release
200
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
2024-04-08 08:00
U
U:AMRN
News Release
200
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
2024-04-08 06:30
U
U:AMRN
News Release
200
New REDUCE-IT(TM) Analyses Show VASCEPA(TM) (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
2024-04-06 15:30
U
U:AMRN
News Release
200
New REDUCE-IT(TM) Analyses Show VASCEPA(TM)/VAZKEPA(TM) (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
2024-04-03 08:00
U
U:AMRN
News Release
200
Amarin Provides Update on VAZKEPA(TM) (Icosapent Ethyl) Intellectual Property Portfolio in Europe
2024-03-25 08:00
U
U:AMRN
News Release
200
Research Evaluating Benefits of VASCEPA(TM)/VAZKEPA(TM) (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo
2024-02-29 07:00
U
U:AMRN
News Release
200
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-15 08:00
U
U:AMRN
News Release
200
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
2024-01-22 07:30
U
U:AMRN
News Release
200
Amarin Chairman & CEO Issue Letter to Shareholders
2024-01-10 07:00
U
U:AMRN
News Release
200
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
2023-12-11 08:00
U
U:AMRN
News Release
200
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-12 09:00
U
U:AMRN
News Release
200
New REDUCE-IT ‚ ® Analyses Show VASCEPA ‚ ® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
2023-11-01 07:00
U
U:AMRN
News Release
200
Amarin Reports Third Quarter 2023 Financial Results
2023-10-31 12:00
U
U:AMRN
News Release
200
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
2023-10-26 08:00
U
U:AMRN
News Release
200
Latest Research Evaluating VASCEPA ‚ ®/VAZKEPA ‚ ® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
2023-10-19 08:00
U
U:AMRN
News Release
200
‚ Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
2023-09-12 08:00
U
U:AMRN
News Release
200
Amarin to Present at the 2023 Cantor Global Healthcare Conference
2023-08-09 16:05
U
U:AMRN
News Release
200
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
2023-08-08 07:00
U
U:AMRN
News Release
200
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA ‚ ® (Icosapent Ethyl) in Israel
2023-08-07 07:01
U
U:AMRN
News Release
200
Scottish Medicines Consortium Accepts VAZKEPA ‚ ® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
2023-08-02 07:11
U
U:AMRN
News Release
200
Amarin Reports Second Quarter 2023 Financial Results
2023-07-31 08:00
U
U:AMRN
News Release
200
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa ‚ ® (Icosapent Ethyl) in Southeast Asia and South Korea
2023-07-26 08:00
U
U:AMRN
News Release
200
Latest Research Evaluating Clinical Benefits of VASCEPA ‚ ®/VAZKEPA ‚ ® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
2023-07-25 16:05
U
U:AMRN
News Release
200
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA ‚ ® (icosapent ethyl) in Spain
2023-07-20 08:00
U
U:AMRN
News Release
200
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
2023-07-18 16:16
U
U:AMRN
News Release
200
Amarin Appoints Patrick Holt as President and Chief Executive Officer
2023-07-18 16:15
U
U:AMRN
News Release
200
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA ‚ ®/VAZKEPA ‚ ® Globally
2023-06-21 09:01
U
U:AMRN
News Release
200
Amarin Announces Vascepa ‚ ® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
2023-06-01 16:30
U
U:AMRN
News Release
200
Amarin to Present at Two Upcoming Investor Conferences
2023-06-01 06:00
U
U:AMRN
News Release
200
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa ‚ ® (Icosapent Ethyl) in Mainland China
2023-05-12 11:00
U
U:AMRN
News Release
200
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa ‚ ®/Vazkepa ‚ ® (Icosapent Ethyl) Reduction of Cardiovascular Events
2023-05-03 07:00
U
U:AMRN
News Release
200
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update